|1.||Wallentin, Lars: 17 articles (02/2012 - 05/2002)|
|2.||Lindahl, Bertil: 12 articles (06/2012 - 05/2002)|
|3.||Lagerqvist, Bo: 12 articles (02/2012 - 12/2003)|
|4.||Wallentin, L: 12 articles (06/2008 - 01/2000)|
|5.||Venge, Per: 10 articles (06/2012 - 05/2002)|
|6.||Heels-Ansdell, Diane: 9 articles (09/2015 - 01/2008)|
|7.||Guyatt, Gordon: 8 articles (09/2015 - 01/2008)|
|8.||Siegbahn, Agneta: 8 articles (02/2010 - 05/2003)|
|9.||Crowther, Mark: 7 articles (09/2015 - 01/2006)|
|10.||Swahn, E: 7 articles (03/2003 - 02/2000)|
03/15/1998 - "We concluded that prolonged (35 days) thrombo prophylaxis with dalteparin is more effective than a standard length (7 days) regimen without increased risk of bleeding complications or other adverse events."
11/01/2015 - "A total of 44 patients received dalteparin with a median duration of 4.2months (range, 2.7-9.4), and four patients were discontinued early due to death (n=3) and major bleeding (n=1). "
06/01/2015 - "Major bleeding was less frequent during dalteparin therapy beyond 6 months. "
11/08/2014 - "However, minor bleeding was more common in the dalteparin group (28/143 [19·6%]) than in the no dalteparin group (13/141 [9·2%]; risk difference 10·4%, 95% CI 2·3-18·4; p=0·01). "
10/01/2013 - "Increasing the dose of dalteparin does not seem to increase the risk of bleeding or formation of a haematoma. "
|2.||Venous Thrombosis (Deep-Vein Thrombosis)
07/01/2000 - "Intravenous or subcutaneous dalteparin is as effective as intravenous UFH when given once or twice daily in the initial management of established deep vein thrombosis (DVT). "
08/01/1996 - "Extensive clinical studies have been conducted to compare the antithrombotic efficacy of dalteparin sodium with that of UFH in surgical thromboprophylaxis, treatment of established deep vein thrombosis (DVT) and the anticoagulation of patients undergoing haemodialysis and haemofiltration. "
12/01/1996 - "Swedish Venous Thrombosis Dalteparin Trial Group."
06/01/2005 - "Dalteparin and other low-molecular-weight heparins are frequently used for the treatment of deep vein thrombosis and for other indications. "
12/01/2001 - "Adjusted per capita costs of deep-vein thrombosis prophylaxis during the rehabilitation stay were $129 lower among subjects treated with dalteparin. "
08/01/2002 - "There was a significant difference in the estimated probability of death and/or myocardial infarction until revascularization or day 90 in favour of dalteparin (log-rank test, P=0.0415) and there was a significant reduction in death and/or myocardial infarction in favour of extended dalteparin treatment at day 45, with a 57% relative risk reduction (P=0.0004). "
11/01/2005 - "Three months dalteparin treatment resulted in a sustained and pronounced reduction of coagulation activity, which corresponds to the observed reduction in death and myocardial infarction during the initial 6 weeks in the FRISC II study. "
11/01/1999 - "The FRIC trial determined there was no difference between dalteparin and UFH in the acute setting for prevention of death or myocardial infarction (MI). "
12/01/1991 - "In an open, dose-finding study, 72 patients with acute myocardial infarction (AMI) were treated with Fragmin (KABI) 240-360 anti-Xa U/kg/24h subcutaneously for 6-10 days. "
05/01/2003 - "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0.016). "
03/08/1993 - "Fragmin administered once daily offers an effective and safe prophylaxis of thrombosis in hip fracture surgery."
10/19/2001 - "We conclude from our data that, in accordance with international studies, an out-patient thrombosis management with Dalteparin is efficacious and safe."
03/01/2012 - "Importantly, we demonstrate that HFUS can be used to monitor the effect of an anticoagulant such as dalteparin until complete resolution of the thrombus. "
01/01/2007 - "Compared to UFH, dalteparin had no significant effect on clinical events and on the IRA late patency, although less thrombus was present. "
03/01/2006 - "Dalteparin blood levels were estimated indirectly over a 12-hour period by measuring anti-Xa activity and by performing a clotting assay known as the ATHU (AHEPA Thrombosis and Hemostasis Unit) test. "
01/01/2011 - "In this observational study, we evaluated the performance of a scoring system, used as a guide for clinicians administering dalteparin to pregnant women at increased risk of venous thromboembolism. "
02/14/2005 - "Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial."
08/17/2004 - "We undertook an international, multicenter, randomized, double-blind, placebo-controlled trial using clinically important outcomes to assess the efficacy and safety of dalteparin in the prevention of venous thromboembolism in such patients. "
08/17/2004 - "Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients."
04/30/2004 - "Dalteparin has been subjected to a large number of well designed randomised clinical trials for the prevention and treatment of venous thromboembolism. "
|1.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|4.||Dalteparin (Dalteparin Sodium)
|5.||Nadroparin (Nadroparin Calcium)
|6.||Aspirin (Acetylsalicylic Acid)
|8.||certoparin (certoparin sodium)
|9.||glucuronyl glucosamine glycan sulfate (Vessel)
|3.||Hip Replacement Arthroplasty (Total Hip Replacement)
|5.||Renal Dialysis (Hemodialysis)